Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-Cola HBC Regulatory News (CCH)

Share Price Information for Coca-Cola HBC (CCH)

Share Price is delayed by 15 minutes
Get Live Data
4,594.00    28.00 (0.61%)
Bid:
4,592.00
Ask:
4,594.00
Spread: 2.00 (0.044%)
Market Cap: £16.74b
CCH Live PriceLast checked at - London Stock Exchange

Intraday Coca-Cola HBC Share Chart

Directorate Change

21 Jun 2017 09:26

RNS Number : 7109I
Coca-Cola HBC AG
21 June 2017
 

FOR IMMEDIATE RELEASE

 

Coca-Cola HBC AG

Composition of the Committees of the Board of Directors of Coca‑Cola HBC AG and determination of a new member of the Board of Directors of Coca‑Cola HBC AG

 

 

Zug, Switzerland - 21 June 2017 - Coca‑Cola HBC AG ("Coca‑Cola HBC" or the "Company") announces today that its board of directors (the "Board") has appointed Ms. Charlotte J. Boyle as a member of the Remuneration Committee, with effect from 20 June 2017.

This appointment has been made pursuant to the announcement released by Coca‑Cola HBC on 15 May 2017 and the election of Ms. Charlotte J. Boyle as a non-executive member of the Board at the Company's annual general meeting held on 20 June 2017, following the retirement of Mr. Antonio D'Amato.

The Board has determined that Ms. Charlotte J. Boyle qualifies as independent under the criteria set forth in the UK Corporate Governance Code.

Aside from the information set out above, no further information is required to be disclosed pursuant to the UK Financial Conduct Authority's Listing Rule 9.6.13 and the new non-executive director does not hold any interests in the shares of Coca‑Cola HBC.

The composition of the Board Committees will be as follows:

Audit Committee

William (Bill) W. Douglas III (Chair)

John P. Sechi

Olusola (Sola) David-Borha

Nomination Committee

Reto Francioni (Chair)

Charlotte J. Boyle

Alexandra Papalexopoulou

Remuneration Committee

Alexandra Papalexopoulou (Chair)

Charlotte J. Boyle

Reto Francioni

Social Responsibility Committee

Anastasios I. Leventis (Chair)

Alexandra Papalexopoulou

José Octavio Reyes

This announcement is made pursuant to Listing Rule 9.6.11.

 

 

 

Enquiries

Coca‑Cola HBC Group

Basak Kotler

Investor Relations Director

Tel: +44 20 37 444 231 basak.kotler@cchellenic.com

Vasso Aliferi

Investor Relations Manager

Tel: +30 210 6183 341

vasso.aliferi@cchellenic.com

Maria Livaniou

Head of Shareowner Service

Tel: +30 210 6183 106

maria.livaniou@cchellenic.com

 

International media contact:

Teneo Blue Rubicon

Rob Morgan

Anushka Mathew

Tel: +44 20 7260 2700 robert.morgan@teneobluerubicon.com anushka.mathew@teneobluerubicon.com

 

Greek media contact:

V+O Communications

Argyro Oikonomou

Tel: +30 211 7501219

 ao@vando.gr

 

 

About Coca‑Cola HBC

Coca-Cola HBC is a leading bottler of The Coca-Cola Company with a sales volume of more than 2 billion unit cases. It has a broad geographic footprint with operations in 28 countries serving a population of approximately 595 million people. Coca-Cola HBC offers a diverse range of non-alcoholic ready to drink beverages in the sparkling, juice, water, sport, energy, tea and coffee categories. Coca-Cola HBC is committed to promoting sustainable development in order to create value for its business and for society. This includes providing products that meet the beverage needs of consumers, fostering an open and inclusive work environment, conducting its business in ways that protect and preserve the environment and contribute to the socio-economic development of the local communities. Coca-Cola HBC is ranked beverage industry leader in the Dow Jones Sustainability World and Europe Indices, and is also included in the FTSE4Good Index.

 

Coca-Cola HBC has a premium listing on the London Stock Exchange (LSE: CCH) and its shares are listed on the Athens Exchange (ATHEX: EEE). For more information, please visit http://www.coca-colahellenic.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALIFFTRSILFID
Date   Source Headline
15th Jun 20265:00 pmRNSDirector/PDMR Shareholding
22nd May 20263:30 pmRNSDirector/PDMR Shareholding
19th May 20263:15 pmRNSDirector/PDMR Shareholding
11th May 20269:00 amRNSDirector Declaration
8th May 20263:15 pmRNSComposition of the Board Committees
8th May 20263:10 pmRNSResult of AGM
7th May 20267:00 amRNSStrong volume drives Q1 sales growth
20th Apr 20263:15 pmRNSDirector/PDMR Shareholding
14th Apr 202612:15 pmRNSNotice of Results
2nd Apr 20267:00 amRNSNotice of AGM, changes to the BoD, dividend dates
1st Apr 20269:15 amRNSTransfer of treasury shares & total voting rights
31st Mar 202611:00 amRNSPublication of Final Terms
27th Mar 20262:45 pmRNSDirector/PDMR Shareholding
27th Mar 20262:15 pmRNSDirector/PDMR Shareholding
26th Mar 20266:18 pmRNSPricing of Issue of Notes
26th Mar 20269:05 amRNSLaunch of Issue of Notes
25th Mar 20261:36 pmRNSPublication of a Prospectus
20th Mar 202611:00 amRNSAnnual Financial Report
19th Mar 20264:55 pmRNSDirector/PDMR Shareholding
19th Mar 20264:45 pmRNSDirector/PDMR Shareholding
18th Mar 20264:15 pmRNSDirector/PDMR Shareholding
18th Mar 202611:35 amRNSDirector/PDMR Shareholding
26th Feb 202611:30 amRNSDirector/PDMR Shareholding
25th Feb 20269:20 amRNSDirector/PDMR Shareholding
24th Feb 20264:55 pmRNSDirector/PDMR Shareholding
24th Feb 20264:50 pmRNSDirector/PDMR Shareholding
23rd Feb 20264:40 pmRNSDirector/PDMR Shareholding
23rd Feb 20264:35 pmRNSDirector/PDMR Shareholding
18th Feb 20264:50 pmRNSDirector/PDMR Shareholding
18th Feb 20264:45 pmRNSDirector/PDMR Shareholding
18th Feb 20264:00 pmRNSDirector/PDMR Shareholding
17th Feb 20263:35 pmRNSDirector/PDMR Shareholding
17th Feb 20263:30 pmRNSDirector/PDMR Shareholding
16th Feb 20262:40 pmRNSDirector/PDMR Shareholding
16th Feb 20262:35 pmRNSDirector/PDMR Shareholding
13th Feb 202610:30 amRNSDirector/PDMR Shareholding
12th Feb 20263:45 pmRNSDirector/PDMR Shareholding
12th Feb 20261:15 pmRNSDirector/PDMR Shareholding
10th Feb 20267:00 amRNSStrong execution and financial performance in 2025
2nd Feb 202610:00 amRNSTransfer of treasury shares & total voting rights
19th Jan 20264:00 pmRNSDirector/PDMR Shareholding
19th Jan 20262:20 pmRNSResult of Extraordinary General Meeting
13th Jan 202611:00 amRNSNotice of Results
5th Jan 202610:00 amRNSDirector/PDMR Shareholding
23rd Dec 20252:45 pmRNSDirector/PDMR Shareholding
23rd Dec 20252:45 pmRNSDirector/PDMR Shareholding
22nd Dec 20252:15 pmRNSDirector/PDMR Shareholding
22nd Dec 20252:15 pmRNSDirector/PDMR Shareholding
18th Dec 20255:00 pmRNSDirector/PDMR Shareholding
18th Dec 20255:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.